Skip to main content
Beximco Pharmaceuticals Ltd. logo

Beximco Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · BXP ISIN · US0885792061 LEI · 213800IMBBD6TIOQGB56 IL Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2019-08-08 Regulatory Filings
Country BD Bangladesh
Listing IL BXP

About Beximco Pharmaceuticals Ltd.

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd. is a manufacturer of generic drugs and active pharmaceutical ingredients (APIs). The company produces a broad portfolio of over 500 products across various therapeutic categories, with a focus on providing access to affordable medicines. It has established a strong market differentiation through a range of high-tech, specialized products, including metered-dose and dry powder inhalers. Serving numerous emerging and developed markets globally, its manufacturing facilities are accredited by major international regulatory authorities, including those of the USA, European Union, Australia, and Canada.

Recent filings

Filing Released Lang Actions
Update on Dividend and Tax legislation changes
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding an update on dividend and tax legislation. While it mentions dividends, it is not a declaration of a specific dividend amount or payment date (DIV), but rather a regulatory clarification regarding tax law compliance. As it is a general regulatory announcement that does not fit into more specific categories like financial reports or shareholder voting, it is best classified as a Regulatory Filing (RNS).
2019-08-08 English
Beximco launches fifth product in the US market
Regulatory Filings Classification · 1% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific corporate development: the launch of a new pharmaceutical product (Nadolol) in the US market. It does not constitute a full financial report, audit, or proxy statement. Since it is a general regulatory announcement regarding company operations that does not fit into more specific categories like M&A or dividend notices, it is classified as a Regulatory Filing (RNS).
2019-07-30 English
Dividend and Tax changes for Bangladesh companies
Notice of Dividend Amount Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding new tax legislation in Bangladesh that impacts the company's dividend policy. While it discusses dividends, it is not a declaration of a specific dividend amount or payment date (DIV), but rather a regulatory update on how legislative changes will affect future policy. As it is a general regulatory announcement that does not fit into more specific categories like dividend declarations or financial reports, it is classified as a Regulatory Filing (RNS).
2019-07-18 English
3rd Quarter Results
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for Beximco Pharmaceuticals Limited for the period ended March 31, 2019. It contains detailed consolidated financial statements, including the Statement of Financial Position and the Statement of Profit or Loss and Other Comprehensive Income. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). 9M 2019
2019-04-29 English
Beximco receives FDA approval for Cyproheptadine
Regulatory Filings Classification · 1% confidence The document is a news release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a specific corporate event: the receipt of US FDA approval for a new pharmaceutical product (Cyproheptadine). It does not fit into specific categories like financial reports, dividend notices, or board changes, and it is not a report publication announcement. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2019-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.